AstraZeneca’s Diabetes Drug, Xigduo, Launched in the UK

cialis Xigduo, Launched in the UK” src=”http://i39.tinypic.com/hwxyt2.jpg” width=”230″ height=”80″ />Type II diabetes patients living in England and Wales have gained access to a new treatment option to improve blood glucose levels after AstraZeneca launched their diabetes drug, Xigduo, earlier this week. Xigduo combines BMS-512148 and metformin in a twice-daily tablet for use in patients inadequately

Continue Reading

Eli Lilly Reveal Positive Clinical Trial Results for Dulaglutide

Eli Lilly has announced the results of their head-to-head clinical study which demonstrates that their investigational GLP-1 glucagon-like peptide 1 receptor agonist, dulaglutide,  is just as effective as Novo Nordisk’s Victoza, the market-leader in the area. The pharmaceutical company revealed the positive top-line results of the sixth clinical trial in their AWARD programme, whereby once-weekly

Continue Reading

Tresiba and Ryzodeq Approved by EU Regulators

European regulators have approved Novo Nordisk’s Tresiba and Ryzodeg, which Novo hopes will challenge Sanofi’s Lantus, the largest selling insulin product globally. The European Commission have granted marketing authorisations for Tresiba (insulin degludec) and Ryzodeg (insulin degludec/insulin aspart) for the treatment of diabetes in adults.

Continue Reading

Dompe Signs Up First Patient for Reparixin Phase III Trial

Italy’s Dompe have confirmed that they have signed up their first patient onto a late-stage clinical trial evaluating reparixin as a possible treatment for type 1 diabetes. The compound, a selective chemokine interleukin-8 inhibitor, has been shown to increase the efficacy of transplantation of insulin-producing pancreatic islets, which the company commented is “the new frontier

Continue Reading

Diabetes Drug, Jentadueto, Reaches UK Market

Patients in the UK with type II diabetes now have access to a new alternative for managing their blood glucose levels with the launch of Boehringer Ingelheim/Eli Lilly’s new combination drug, Jentadueto, being launched in the UK this week. Jentadueto combines two antiglycaemic therapies – the veteran drug metformin with the dipeptidyl peptidase (DPP)-IV inhibitor

Continue Reading

Novo Nordisk Increase Staff in Emerging Markets

Novo Nordisk has revealed plans to expand their treatment for diabetes in emerging markets by employing roughly 1,000 additional employees over the next two years. Some of the emerging markets that Novo Nordisk are planning to expand in include Egypt, Vietnam, Colombia, Malaysia, Ukraine and Indonesia. As the pharmaceutical market in Europe, for example, slows

Continue Reading

Generic Actos Launched by Mylan, Teva and Ranbaxy

Mylan, Teva and Ranbaxy announced on Friday that they have each launched generic forms of Takeda’s blockbuster type 2 diabetes drug Actos in the US. The generic drugmakers are sharing 180-day exclusivity for the generic versions of the branded medication, which receives in sales of roughly $2.7 billion a year across America. Actos (pioglitazone) is

Continue Reading

Jentadueto Receives European Commission Marketing Authorisation

European regulators have given approval to Boehringer Ingelheim and Eli Lilly’s diabetes combo drug, Jentadueto. The pharmaceutical organisations announced earlier today that they received marketing authorisation from the European Commission (EC) for Jentadueto, which combines metformin with the dipeptidyl peptidase (DPP)-IV inhibitor Trajenta (linagliptin) in a single pill. The approval was expected after the European

Continue Reading